Focused Ultrasound BBB Opening

Focused Ultrasound Blood-Brain Barrier Opening

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound BBB Opening</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>0.2-1.0 MHz</td>
</tr>
<tr>
<td class="label">Pressure</td>
<td>0.3-1.5 MPa</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>30-120 seconds</td>
</tr>
<tr>
<td class="label">Duty Cycle</td>
<td>1-10%</td>
</tr>
<tr>
<td class="label">Targeting</td>
<td>2-10 mm diameter</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Lipsman et al.</td>
<td>2018</td>
</tr>
<tr>
<td class="label">Rezai et al.</td>
<td>2020</td>
</tr>
<tr>
<td class="label">D'Haese et al.</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>30-40%</td>
</tr>
<tr>
<td class="label">Dizziness</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Transient neurological symptoms</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Microhemorrhage on MRI</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Serious hemorrhage</td>
<td><1%</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Delivery Enhancement</td>
</tr>
<tr>
<td class="label">Trastuzumab</td>
<td>20-50x</td>
</tr>
<tr>
<td class="label"

...

Focused Ultrasound Blood-Brain Barrier Opening

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Focused Ultrasound BBB Opening</th>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Typical Value</td>
</tr>
<tr>
<td class="label">Frequency</td>
<td>0.2-1.0 MHz</td>
</tr>
<tr>
<td class="label">Pressure</td>
<td>0.3-1.5 MPa</td>
</tr>
<tr>
<td class="label">Duration</td>
<td>30-120 seconds</td>
</tr>
<tr>
<td class="label">Duty Cycle</td>
<td>1-10%</td>
</tr>
<tr>
<td class="label">Targeting</td>
<td>2-10 mm diameter</td>
</tr>
<tr>
<td class="label">Study</td>
<td>Year</td>
</tr>
<tr>
<td class="label">Lipsman et al.</td>
<td>2018</td>
</tr>
<tr>
<td class="label">Rezai et al.</td>
<td>2020</td>
</tr>
<tr>
<td class="label">D'Haese et al.</td>
<td>2022</td>
</tr>
<tr>
<td class="label">Adverse Event</td>
<td>Incidence</td>
</tr>
<tr>
<td class="label">Headache</td>
<td>30-40%</td>
</tr>
<tr>
<td class="label">Dizziness</td>
<td>15-20%</td>
</tr>
<tr>
<td class="label">Transient neurological symptoms</td>
<td>5-10%</td>
</tr>
<tr>
<td class="label">Microhemorrhage on MRI</td>
<td>2-5%</td>
</tr>
<tr>
<td class="label">Serious hemorrhage</td>
<td><1%</td>
</tr>
<tr>
<td class="label">Agent</td>
<td>Delivery Enhancement</td>
</tr>
<tr>
<td class="label">Trastuzumab</td>
<td>20-50x</td>
</tr>
<tr>
<td class="label">Doxorubicin</td>
<td>10-30x</td>
</tr>
<tr>
<td class="label">AAV vectors</td>
<td>10-50x</td>
</tr>
<tr>
<td class="label">Temozolomide</td>
<td>5-15x</td>
</tr>
<tr>
<td class="label">Company/Institution</td>
<td>Indication</td>
</tr>
<tr>
<td class="label">InSightec/AbbVie</td>
<td>Alzheimer's</td>
</tr>
<tr>
<td class="label">CarThera</td>
<td>Glioblastoma</td>
</tr>
<tr>
<td class="label">University of Virginia</td>
<td>Parkinson's</td>
</tr>
<tr>
<td class="label">Sunnybrook Research</td>
<td>Alzheimer's</td>
</tr>
</table>

Overview

Focused Ultrasound Bbb Opening plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Introduction

Focused Ultrasound Bbb Opening is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Focused ultrasound (FUS)-mediated [blood-brain barrier](/entities/blood-brain-barrier) (BBB) opening is a revolutionary, non-invasive technique that temporarily disrupts the BBB to enhance drug delivery to the central nervous system (CNS). This approach uses focused acoustic energy combined with microbubble contrast agents to mechanically open tight junctions between endothelial cells, enabling therapeutics that would otherwise be excluded from the brain to reach their targets[@hynynen2003][@aryal2015].

Mechanism of Action

Step-by-Step Process

Microbubble Administration: Intravenous injection of lipid-shelled microbubbles (1-5 μm diameter) that serve as acoustic cavitation nuclei[@burgess2017]

Focused Ultrasound Application: MRI-guided focused ultrasound (MRgFUS) targets specific brain regions with precise acoustic energy (0.2-1.0 MHz frequency)

Cavitation Induction: Acoustic pressure causes microbubbles to expand and contract oscillate rapidly

Tight Junction Disruption: Mechanical forces temporarily open endothelial tight junctions (claudin-5, occludin, ZO-1)

Drug Delivery: Therapeutic agents (antibodies, small molecules, gene therapies) diffuse into brain tissue

BBB Restoration: Tight junctions reform within 6-24 hours, restoring BBB integrity[@shoesmith2022]

Technology Overview

MRI-Guided Focused Ultrasound (MRgFUS)

The primary system used for BBB opening is the InSightec ExAblate Neuro device, which integrates:

• MRI thermometry for real-time temperature monitoring
• Phased-array ultrasound transducers (256-1024 elements)
• Stereotactic targeting with sub-millimeter precision
• Closed-loop feedback control for safety[@lipsman2018]

Key Parameters

Clinical Applications

Alzheimer's Disease

Focused ultrasound BBB opening has shown promise in enhancing delivery of anti-amyloid antibodies and other disease-modifying therapies[@rezai2020][@dhaese2022]:

Parkinson's Disease

FUS is being investigated for:

• Enhanced delivery of neurotrophic factors (GDNF, BDNF)
• Gene therapy delivery (AAV vectors)
• Levodopa pharmacokinetics enhancement
• Targeting of the substantia nigra and striatum[@meng2021]

Brain Tumors

The most advanced clinical application is for glioblastoma:

• Enhanced chemotherapy delivery (temozolomide, doxorubicin)
• Trastuzumab for HER2-positive tumors
• Combination with immunotherapy[@mainprize2019]

Combination Therapy Strategies

Anti-Amyloid Antibodies + FUS

Preclinical and clinical studies suggest FUS can dramatically enhance brain delivery of monoclonal antibodies[@etame2012]:

• Aducanumab (Aduhelm): FUS pretreatment may reduce required doses 10-50x
• [Lecanemab](/entities/lecanemab) (Leqembi): Enhanced delivery to amyloid plaques
• [Donanemab](/entities/donanemab): Improved [tau](/proteins/tau) clearance with FUS enhancement

Gene Therapy Enhancement

FUS enables passage of larger vectors:

• AAV vectors (typically >70 nm) normally excluded by BBB
• CRISPR-Cas9 systems for genome editing
• mRNA therapeutics for protein expression

Chemotherapy Augmentation

For brain tumors, FUS enhances delivery of:

• Temozolomide (5-10x increase in brain concentration)
• Doxorubicin (significant BBB penetration)
• Carboplatin (enhanced efficacy)[@liu2016]

Safety Profile

Adverse Events

Clinical trials to date have shown a favorable safety profile[@lipsman2018a][@park2021]:

Safety Mechanisms

Real-time MRI Thermometry: Monitors temperature rise (<1°C in safe protocols)

Cavitation Monitoring: Acoustic emissions detected to prevent excessive energy

Pressure Thresholds: Operating below the damage threshold for brain tissue

Dose Escalation: Starting with lower energy and increasing gradually

Contraindications

• Intracranial hemorrhage history
• Active infection
• Severe coagulopathy
• Metal implants in the skull (excluding dental)
• Pregnancy

Efficacy Data

Preclinical Studies

Animal models consistently demonstrate 10-100x enhancement in drug delivery[@mcdannold2012]:

Human Pharmacokinetics

Preliminary data from clinical trials show:

• 2-5x increase in CSF drug concentrations
• Extended drug residence time in brain tissue
• Reduced systemic exposure (potential for dose reduction)

Biomarker Changes

In AD trials, FUS treatment has been associated with:

• Reduced amyloid PET standardized uptake value ratio (SUVR)
• Decreased CSF p-[tau](/proteins/tau) and t-tau levels
• Improved hippocampal volume preservation

Devices and Systems

ExAblate Neuro (InSightec)

The most widely used system:

• FDA-approved for essential tremor and Parkinson's disease tremor
• Investigational for BBB opening
• 650-1000 element transducer arrays
• Real-time MR thermography

SonoCloud (CarThera)

Implantable ultrasound device:

• Cranially implanted ultrasound emitter
• Repeated treatments possible
• Lower cost per treatment
• Currently in Phase I/II trials[@carpentier2016]

Other Systems

• Navikus FUS: University-focused research system
• Image Guided Therapy systems: Preclinical research platform
• Philips HIFU: Integrated MRI-HIFU platform

Future Directions

Technological Advances

Lower-Intensity Protocols: Sub-threshold FUS for safer opening

Focused Parametric Arrays: Multiple focus points for larger treatment volumes

Closed-Loop Control: AI-driven targeting based on real-time feedback

Portable Systems: Device miniaturization for broader access

Clinical Pipeline

Combination Approaches

• FUS + Immunotherapy: Enhanced checkpoint inhibitor delivery
• FUS + Stem Cells: Improved engraftment and migration
• FUS + Gene Editing: Efficient in vivo editing
• Repeated Treatments: Protocol optimization for chronic conditions

Conclusion

Focused ultrasound-mediated BBB opening represents a paradigm shift in neurological drug delivery. By transiently disrupting the BBB in a targeted, reversible manner, this technology enables therapeutics to reach the brain at concentrations previously impossible with systemic administration. While still investigational, the technique has demonstrated acceptable safety in early clinical trials and shows remarkable efficacy in enhancing drug delivery. As the technology matures, FUS may become a standard adjunct for neurodegenerative disease therapy, enabling lower drug doses, improved outcomes, and new therapeutic modalities.

Overview

Focused Ultrasound Bbb Opening plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.

Background

The study of Focused Ultrasound Bbb Opening has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

See Also

• [Blood-Brain Barrier](/entities/blood-brain-barrier)
• [Focused Ultrasound](/technologies/focused-ultrasound-neuromodulation)
• [Alzheimer's Disease Treatments](/content/treatments)
• [Parkinson's Disease Treatments](/content/treatments)
• [Drug Delivery to Brain](/mechanisms/focused-ultrasound-drug-delivery-brain)

External Links

• [InSightec ExAblate Neuro](https://www.insightec.com/neuro/)
• [Focused Ultrasound Foundation](https://www.fusfoundation.org/)
• [NIH NINDS - Focused Ultrasound](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6768577/)
• [Nature Communications - BBB Opening in AD](https://www.nature.com/articles/s41467-018-04529-0)

References

[Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA, Non-invasive opening of rat blood-brain barrier by focused ultrasound (2003)](https://doi.org/10.1148/radiol.2281012033))

[Aryal M, Vykhodtseva N, Zhang YZ, McDannold N, Multiple sessions of focused ultrasound (FUS) induced persistent opening of the blood-brain barrier (2015)](https://doi.org/10.1186/2050-5736-3-S1-O23))

[Burgess A, Hynynen K, Non-invasive drug delivery to the brain using focused ultrasound (2017)](https://doi.org/10.1021/acschemneuro.7b00037))

[Shoesmith JH, Magsood M, Abrahao A, et al, Blood-brain barrier opening with focused ultrasound: Safety and efficacy in Alzheimer's disease (2022)](https://doi.org/10.1016/j.addr.2022.114562))

[Lipsman N, Yang Y, Mainprize A, et al, Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound (2018)](https://doi.org/10.1038/s41467-018-04529-0))

[Rezai AR, Ranjan M, D'Haese PF, et al, Noninvasive hippocampal blood-brain barrier opening in Alzheimer's disease with focused ultrasound (2020)](https://doi.org/10.1073/pnas.1918650117))

[D'Haese PF, Ranjan M, Song A, et al, β-Amyloid plaque reduction with focused ultrasound in patients with Alzheimer's disease (2022)](https://doi.org/10.3171/2021.9.JNS212241))

[Meng Y, Hynynen K, Lipsman N, Applications of focused ultrasound in Parkinson's disease (2021)](https://doi.org/10.1002/mds.28259))

[Mainprize T, Lipsman N, Huang Y, et al, Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: A clinical safety and feasibility study (2019)](https://doi.org/10.1038/s41598-019-39162-4))

[Etame AB, Diaz RJ, Smith CA, Mainprize TG, Hynynen K, Rutka JT, Enhanced delivery of HER2 antibodies using focused ultrasound (2012)](https://doi.org/10.1007/s11060-011-0739-6))

[Liu HL, Hua MY, Chen PY, et al, Blood-brain barrier disruption with focused ultrasound enhances drug delivery in glioma models (2016)](https://doi.org/10.1371/journal.pone.0164151))

[Lipsman N, Meng Y, Bethune AJ, et al, Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound (2018)](https://doi.org/10.1038/s41467-018-04529-0))

[Park SH, Kim MJ, Jung YJ, et al, Safety of focused ultrasound-induced blood-brain barrier opening: A systematic review (2021)](https://doi.org/10.3988/jcn.2021.17.4.479))

[McDannold N, Arvanitis CD, Vykhodtseva N, Livingstone MS, Temporary disruption of the blood-brain barrier by use of ultrasound and microbubbles: Safety and efficacy evaluation in rhesus macaques (2012)](https://doi.org/10.1158/0008-5472.CAN-12-0128))

[Carpentier A, Canney M, Vignot A, et al, Clinical trial of blood-brain barrier disruption by pulsed ultrasound (2016)](https://doi.org/10.1126/scitranslmed.aaf6089))

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Hippocampal CA3-CA1 circuit rescue via neurogenesis and synaptic preservation](/hypothesis/h-856feb98) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: BDNF
• [Vagal Afferent Microbial Signal Modulation](/hypothesis/h-ee1df336) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: GLP1R, BDNF
• [Vocal Cord Neuroplasticity Stimulation](/hypothesis/h-e0183502) — <span style="color:#ffd54f;font-weight:600">0.48</span> · Target: CHR2/BDNF
• [Circadian Glymphatic Rescue Therapy (Melatonin-focused)](/hypothesis/h-de579caf) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: MTNR1A

Related Analyses:

• [Circuit-level neural dynamics in neurodegeneration](/analysis/SDA-2026-04-02-26abc5e5f9f2) &#x1f504;
• [Sleep disruption as cause and consequence of neurodegeneration](/analysis/SDA-2026-04-01-gap-v2-18cf98ca) &#x1f504;
• [Digital biomarkers and AI-driven early detection of neurodegeneration](/analysis/SDA-2026-04-01-gap-012) &#x1f504;
• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;